Galmed Pharmaceuticals Ltd

Most Recent

  • uploads///ecg _
    Company & Industry Overviews

    Galmed Stock Rose Over 26% on ‘Overweight’ Rating

    Today, Galmed Pharmaceuticals (GLMD) soared as Cantor Fitzgerald initiated coverage on the stock with an “overweight” rating and a target price of $59.

    By Sarah Collins
  • uploads///feit
    Company & Industry Overviews

    Why Galmed Pharmaceuticals Stock Rose 151% on June 12

    Galmed Pharmaceuticals stock rose 151.3% on June 12. The stock closed at $17.59, which is a 387% increase from its 52-week low of $3.61 on February 14.

    By Daniel Collins
  • uploads///NASH
    Company & Industry Overviews

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.